1. Home
  2. SLE vs APM Comparison

SLE vs APM Comparison

Compare SLE & APM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Super League Enterprise Inc.

SLE

Super League Enterprise Inc.

HOLD

Current Price

$2.75

Market Cap

5.0M

ML Signal

HOLD

Logo Aptorum Group Limited

APM

Aptorum Group Limited

HOLD

Current Price

$0.70

Market Cap

5.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SLE
APM
Founded
2014
2010
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Services-Misc. Amusement & Recreation
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
5.6M
IPO Year
2019
2018

Fundamental Metrics

Financial Performance
Metric
SLE
APM
Price
$2.75
$0.70
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$60.00
N/A
AVG Volume (30 Days)
18.3K
26.3K
Earning Date
05-14-2026
03-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,064,000.00
N/A
Revenue This Year
$24.86
N/A
Revenue Next Year
$49.77
N/A
P/E Ratio
N/A
N/A
Revenue Growth
90.41
N/A
52 Week Low
$0.48
$0.60
52 Week High
$11.43
$4.47

Technical Indicators

Market Signals
Indicator
SLE
APM
Relative Strength Index (RSI) 43.59 34.93
Support Level $2.66 $0.65
Resistance Level $3.43 $0.89
Average True Range (ATR) 0.20 0.05
MACD 0.02 -0.00
Stochastic Oscillator 42.03 42.86

Price Performance

Historical Comparison
SLE
APM

About SLE Super League Enterprise Inc.

Super League Enterprise Inc is the rocket ship to the metaverse. It is a creator and publisher of content experiences and media solutions across the globe's immersive platforms. Its solutions provide incomparable access to massive audiences that gather in immersive digital spaces to socialize, play, explore, collaborate, shop, learn, and create. The company offers a complete range of development, distribution, monetization, and optimization capabilities designed to engage users through dynamic, energized programs. It generates revenue from advertising, including immersive game world and experience publishing and in-game media products, direct-to-consumer offers, including in-game items, e-commerce, game passes and ticketing and digital collectibles, and content and technology.

About APM Aptorum Group Limited

Aptorum Group Ltd is a clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.

Share on Social Networks: